Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Various markers characterize the complex inflammatory processes seen in chronic inflammatory bowel disease (IBD) including calprotectin, a complex of two S100 proteins, which has been evaluated and validated as a faecal marker of inflammation. However, the systemic and mucosal expression patterns of calprotectin and related S100 proteins are not well characterized in this disease. The objective of this study was to assess serum and mucosal levels of calprotectin, S100A12 and soluble receptor for advanced glycation end products (sRAGE), a putative S100 ligand, in a paediatric population with IBD. MATERIAL AND METHODS: Children were enrolled at diagnosis of IBD, along with groups of children without IBD. Standard inflammatory markers and disease activity scores were collated. Calprotectin, S100A12 and sRAGE levels in serum and biopsy culture supernatants were measured by ELISA and tissue distribution of S100 proteins was investigated by immunohistochemistry. RESULTS: Serum and mucosal calprotectin and S100A12 levels were increased in children with IBD as compared with non-IBD controls. Serum calprotectin levels correlated with S100A12 levels and with disease activity scores in children with IBD. sRAGE levels were not increased in IBD. S100A8, S100A9 and S100A12 were abundantly expressed throughout the lamina propria and epithelium in inflamed mucosa. In contrast, these proteins were present in the lamina propria, but not the epithelium, in non-inflamed mucosa. CONCLUSIONS: Serum calprotectin and S100A12 are increased in children with IBD and indicate disease activity. Elevated levels of these proteins are present in the colonic mucosa and may contribute to the pathogenesis of IBD. Furthermore, an imbalance between sRAGE and S100A12 may contribute to inflammatory changes present in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J.-F., Gasche, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,409 · cited 2×
“Disease location was based on endoscopic and histologic findings and classified for CD as L1 (terminal ileum), L2 (colon), L3 (ileocolon), L4 (upper GI) or a combination, for UC as E1 (ulcerative proctitis), E2 (left-sided UC) or E3 (extensive UC) as outlined by the Montreal classification [25].”
MethodInflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059 · cited 1×
“The aetiology of IBD is not fully understood but the currently accepted hypothesis is that an initiator, likely to be a gastrointestinal microorganism or its by-product, stimulates and maintains a dysregulated immune response in a disrupted gastrointestinal epithelium in genetically predisposed individuals [1,2].”
BackgroundRAGE Mediates a Novel Proinflammatory Axis
Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., Avila, C., Kambham, N., Bierhaus, A., Nawroth, P., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80801-6 · Cited by 1,864 · cited 3×
“This could promote inflammation in IBD, as RAGE ligation initiates pro-inflammatory cytokine release [17].”
BackgroundRyckman, C., Vandal, K., Rouleau, P., Talbot, M., & Tessier, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3233 · Cited by 858 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundTibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., & Bjarnason, I. (2000) · Gastroenterology · doi:10.1053/gast.2000.8523 · Cited by 759 · cited 1×
“Furthermore, faecal calprotectin is becoming widely accepted as a non-invasive tool in diagnosis [42], as well as having roles in the monitoring of remission, prediction of relapse [33,43] and monitoring of mucosal healing [31] in IBD.”
BackgroundD'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., & Rutgeerts, P. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 745 · cited 1×
“TNFa is a prominent cytokine that is associated with the pathogenesis of IBD and the symptoms of CD can resolve following anti-TNFa antibody treatment [19].”
BackgroundInfluentialAntimicrobial actions of calcium binding leucocyte L1 protein, calprotectin
Steinbakk, M., Naess-Andresen, C.-F., Fagerhol, M. K., Lingaas, E., Dale, I., & Brandtzaeg, P. (1990) · The Lancet · doi:10.1016/0140-6736(90)93237-j · Cited by 514 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundA simple method for assessing intestinal inflammation in Crohn's disease
Tibble, J., Teahon, K., Thjodleifsson, B., Roseth, A., Sigthorsson, G., Bridger, S., Foster, R., Sherwood, R., Fagerhol, M., & Bjarnason, I. (2000) · Gut · doi:10.1136/gut.47.4.506 · Cited by 492 · cited 1×
“In an adult population of patients with active CD, a single measure of faecal calprotectin distinguished these patients from patients with no organic intestinal disease, with 100% sensitivity and 97% specificity [32].”
BackgroundTibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 441 · cited 1×
“Furthermore, faecal calprotectin is becoming widely accepted as a non-invasive tool in diagnosis [42], as well as having roles in the monitoring of remission, prediction of relapse [33,43] and monitoring of mucosal healing [31] in IBD.”
BackgroundGoova, M. T., Li, J., Kislinger, T., Qu, W., Lu, Y., Bucciarelli, L. G., Nowygrod, S., Wolf, B. M., Caliste, X., Yan, S. F., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61723-3 · Cited by 431 · cited 1×
“Decreased serum sRAGE levels are associated with an increased risk of coronary artery disease [22] and suppression of the ligand-RAGE axis by sRAGE is a possible target for therapeutic intervention [18,23].”
BackgroundPathogenesis and immune mechanisms of chronic inflammatory bowel diseases.
Sartor, R. B. (1997) · PubMed · Cited by 391
Falcone, C., Emanuele, E., D’Angelo, A., Buzzi, M. P., Belvito, C., Cuccia, M., & Geroldi, D. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160342.20342.00 · Cited by 377 · cited 1×
“Decreased serum sRAGE levels are associated with an increased risk of coronary artery disease [22] and suppression of the ligand-RAGE axis by sRAGE is a possible target for therapeutic intervention [18,23].”
BackgroundCentral role of RAGE-dependent neointimal expansion in arterial restenosis
Sakaguchi, T., Yan, S. F., Yan, S. D., Belov, D., Rong, L. L., Sousa, M., Andrassy, M., Marso, S. P., Duda, S., Arnold, B., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17115 · Cited by 367 · cited 1×
“Soluble RAGE (sRAGE) is a splice variant of RAGE [20] and can function as a RAGE antagonist [21].”
BackgroundYui, S., Nakatani, Y., & Mikami, M. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.753 · Cited by 328 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundFoell, D., Kucharzik, T., Kraft, M., Vogl, T., Sorg, C., Domschke, W., & Roth, J. (2003) · Gut · doi:10.1136/gut.52.6.847 · Cited by 279 · cited 1×
“Preliminary investigations also find raised levels of S100A12 in the sera of adult IBD patients [34], and recently we reported increased S100A12 levels in the stool of paediatric patients at diagnosis of IBD [35].”
BackgroundHenderson, A. R. (1993) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329303000601 · Cited by 258 · cited 2×
“Percentage sensitivity and specificity were calculated as described by Henderson [29].”
MethodRoth, J., Burwinkel, F., van den Bos, C., Goebeler, M., Vollmer, E., & Sorg, C. (1993) · Blood · doi:10.1182/blood.v82.6.1875.1875 · Cited by 233
Proinflammatory properties of the human S100 protein S100A12
Yang, Z., Tao, T., Raftery, M. J., Youssef, P., Di Girolamo, N., & Geczy, C. L. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.986 · Cited by 233 · cited 3×
“S100A12 levels in serum and culture supernatants were measured using an ELISA method, described previously [16].”
BackgroundMethodSelf-citationImproved assay for fecal calprotectin
Tøn, H., Brandsnes, Ø., Dale, S., Holtlund, J., Skuibina, E., Schjønsby, H., & Johne, B. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00206-5 · Cited by 226 · cited 3×
“Calprotectin levels in serum and culture supernatants were measured according to the manufacturer’s instructions using the PhiCal test (Nycomed Pharma AS, Oslo, Norway), which is based on an affinitypurified rabbit polyclonal sandwich ELISA [27].”
MethodInfluentialRobinson, M. J., Tessier, P., Poulsom, R., & Hogg, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m102950200 · Cited by 214 · cited 1×
“Furthermore, the distribution of S100 staining in the inflamed mucosa suggests these S100s, particularly S100A9, were secreted and localized to the extracellular matrix possibly because of the high affinity of S100A9 for heparan sulphate glycosaminoglycans [38].”
BackgroundMonitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations
Foell, D., Wittkowski, H., Hammerschmidt, I., Wulffraat, N., Schmeling, H., Frosch, M., Horneff, G., Kuis, W., Sorg, C., & Roth, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20125 · Cited by 177 · cited 2×
“Decreased serum sRAGE levels are associated with an increased risk of coronary artery disease [22] and suppression of the ligand-RAGE axis by sRAGE is a possible target for therapeutic intervention [18,23].”
BackgroundMalherbe, P., Richards, J. G., Gaillard, H., Thompson, A., Diener, C., Schuler, A., & Huber, G. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00174-6 · Cited by 156 · cited 1×
“Soluble RAGE (sRAGE) is a splice variant of RAGE [20] and can function as a RAGE antagonist [21].”
BackgroundPediatric gastrointestinal disease
Biller, J. A. (2001) · Gastroenterology · doi:10.1016/s0016-5085(01)70142-4 · Cited by 155
NF-κB/Rel/IκB: Implications in gastrointestinal diseases
Schmid, R. M., & Adler, G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70374-x · Cited by 154
Reddy, M. A., Li, S.-L., Sahar, S., Kim, Y.-S., Xu, Z.-G., Lanting, L., & Natarajan, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511425200 · Cited by 152
Novel Intra- and Inter-molecular Sulfinamide Bonds in S100A8 Produced by Hypochlorite Oxidation
Raftery, M. J., Yang, Z., Valenzuela, S. M., & Geczy, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101566200 · Cited by 125 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundSelf-citationOxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8
Harrison, C. A., Raftery, M. J., Walsh, J., Alewood, P., Iismaa, S. E., Thliveris, S., & Geczy, C. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8561 · Cited by 122 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundSelf-citationFecal S100A12: A novel noninvasive marker in children with Crohnʼs disease
de Jong, N., Leach, S. T., & Day, A. S. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.ibd.0000227626.72271.91 · Cited by 122 · cited 1×
“Preliminary investigations also find raised levels of S100A12 in the sera of adult IBD patients [34], and recently we reported increased S100A12 levels in the stool of paediatric patients at diagnosis of IBD [35].”
BackgroundSelf-citationHanai, H., Takeuchi, K., Iida, T., Kashiwagi, N., Saniabadi, A. R., Matsushita, I., Sato, Y., Kasuga, N., & Nakamura, T. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000042243.47279.87 · Cited by 122 · cited 1×
“Furthermore, faecal calprotectin is becoming widely accepted as a non-invasive tool in diagnosis [42], as well as having roles in the monitoring of remission, prediction of relapse [33,43] and monitoring of mucosal healing [31] in IBD.”
BackgroundA protein containing the cystic fibrosis antigen is an inhibitor of protein kinases
Murao, S., Collart, F. R., & Huberman, E. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83189-1 · Cited by 120
Lügering, N., Stoll, R., Kucharzik, T., Schmid, K. W., Rohlmann, G., Burmeister, G., Sorg, C., & Domschke, W. (1995) · Digestion · doi:10.1159/000201267 · Cited by 115 · cited 1×
“Morreover, epithelial cells [39], eosinophils [40] and keratinocytes [41] present in the intestinal mucosa have also been reported to express calprotectin and may be a potential source in the context of IBD.”
BackgroundYen, T., Harrison, C. A., Devery, J. M., Leong, S., Iismaa, S. E., Yoshimura, T., & Geczy, C. L. (1997) · Blood · doi:10.1182/blood.v90.12.4812 · Cited by 108
Self-citationBrandtzæg, P., Dale, I., & Fagerhol, M. K. (1987) · American Journal of Clinical Pathology · doi:10.1093/ajcp/87.6.681 · Cited by 99 · cited 1×
“Morreover, epithelial cells [39], eosinophils [40] and keratinocytes [41] present in the intestinal mucosa have also been reported to express calprotectin and may be a potential source in the context of IBD.”
BackgroundChanging the Conformation State of Cytochrome b 558 Initiates NADPH Oxidase Activation
Berthier, S., Paclet, M.-H., Lerouge, S., Roux, F., Vergnaud, S., Coleman, A. W., & Morel, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209755200 · Cited by 90 · cited 1×
“Calprotectin, a prominent component of neutrophils comprising 40% of their total cytosolic proteins, is suggested to play a role in myeloid cell differentiation and function [3] and is postulated to have intracellular roles that include control of the cell cycle, regulation of Ca(2) homeostasis, inhibition of specific…”
BackgroundRelationship of Common Laboratory Parameters to the Activity of Crohn's Disease in Children
Hyams, J. S., Mandel, F. S., Ferry, G. D., Gryboski, J. D., Kibort, P. M., Kirschner, B. S., Griffiths, A. M., Katz, A. J., & Boyle, J. T. (1992) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-199202000-00017 · Cited by 73
Berntzen, H. B., Fagerhol, M. K., Østensen, M., et al. (1991) · PubMed · Cited by 58
Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders
Røseth, A. G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00375-x · Cited by 47 · cited 1×
“Furthermore, faecal calprotectin is becoming widely accepted as a non-invasive tool in diagnosis [42], as well as having roles in the monitoring of remission, prediction of relapse [33,43] and monitoring of mucosal healing [31] in IBD.”
BackgroundEffects of calprotectin in avridine‐induced arthritis
Brun, J. G., Håland, G., Haga, H., Fagerhol, M. K., & Jonsson, R. (1995) · Apmis · doi:10.1111/j.1699-0463.1995.tb01100.x · Cited by 45 · cited 1×
“The complete spectrum of S100A8, S100A9 and calprotectin activity has yet to be defined, but it is clear these proteins have extracellular functions including antimicrobial and antifungal activity [9], inhibition of immunoglobulin production [10], neutrophil chemotaxis [11], induction of apoptosis [12], regulation of…”
BackgroundThe distribution of the antimicrobial protein, calprotectin, in normal oral keratinocytes
Eversole, L. R., Miyasaki, K. T., & Christensen, R. E. (1992) · Archives of Oral Biology · doi:10.1016/0003-9969(92)90068-j · Cited by 43 · cited 1×
“Morreover, epithelial cells [39], eosinophils [40] and keratinocytes [41] present in the intestinal mucosa have also been reported to express calprotectin and may be a potential source in the context of IBD.”
BackgroundSopalla, C., Leukert, N., Sorg, C., & Kerkhoff, C. (2002) · Biological Chemistry · doi:10.1515/bc.2002.213 · Cited by 41
Cited by
Calprotectin: from biomarker to biological function
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324855 · Cited by 500
Inflammation-associated S100 proteins: new mechanisms that regulate function
Goyette, J., & Geczy, C. L. (2011) · Amino Acids · doi:10.1007/s00726-010-0528-0 · Cited by 345
Self-citationSIPPONEN, T., KÄRKKÄINEN, P., SAVILAHTI, E., KOLHO, K. ‐., NUUTINEN, H., TURUNEN, U., & FÄRKKILÄ, M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03835.x · Cited by 324
Rodríguez, A., Ezquerro, S., Méndez-Giménez, L., Becerril, S., & Frühbeck, G. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00297.2015 · Cited by 282
Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B. I., & Lambert, M. (2009) · Rheumatology · doi:10.1093/rheumatology/kep199 · Cited by 190
Metadata
- Authors
- Leach, S. T., Yang, Z., Messina, I., Song, C., Geczy, C. L., Cunningham, A. M., & Day, A. S.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 42
- Issue
- 11
- Pages
- 1321-1331
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2002107602
- Cited by
- 180
- References
- 40
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.